GP350 CAR-T for Relapse/Refractory and Epstein-Barr Virus Infection Associated Lymphoid Neoplasms

This is a Phase 1/Phase 2 open-label, single-arm clinical study of GP350 CAR-T for Relapse/Refractory and Epstein-Barr virus infection associated lymphoid neoplasms. Each participant will undergo leukapheresis after enrolment, receive treatment of the conditioning chemotherapy, and an intravenous infusion of CAR-T cells. Each participant will proceed through the following study procedures: * Screening * Enrollment/Leukapheresis * Conditioning chemotherapy * CAR T treatment * Post-treatment assessment * Long-term follow-up

NCT Number	NCT07306156
Lead Sponsor	Zhimin Zhai Collaborators: Zeno Therapeutics Pte. Ltd
Conditions	EBV Associated Lymphoid Neoplasms
Enrollment	24 participants
Start Date	2025-11-10
Primary Completion	2030-11-10 (estimated)
Study Completion	2032-11-20 (estimated)
Updated on ClinicalTrials.gov	2025-12-29